Hyam Levitsky - Net Worth and Insider Trading
Hyam Levitsky Net Worth
The estimated net worth of Hyam Levitsky is at least $10 Million dollars as of 2025-04-28. Hyam Levitsky is the EVP, Research & CSO of Juno Therapeutics Inc and owns about 116,700 shares of Juno Therapeutics Inc (JUNO) stock worth over $10 Million. Details can be seen in Hyam Levitsky's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Hyam Levitsky has not made any transactions after 2016-06-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Hyam Levitsky
Hyam Levitsky Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Hyam Levitsky owns 4 companies in total, including Replimune Group Inc (REPL) , Juno Therapeutics Inc (JUNO) , and Agenus Inc (AGEN) among others .
Click here to see the complete history of Hyam Levitsky’s form 4 insider trades.
Insider Ownership Summary of Hyam Levitsky
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| REPL | Replimune Group Inc | 2018-07-19 | director |
| JUNO | Juno Therapeutics Inc | 2017-02-07 | EVP & Research & CSO |
| AGEN | Agenus Inc | 2006-09-13 | director |
 | | 2022-01-25 | President of R&D |
Hyam Levitsky Latest Holdings Summary
Hyam Levitsky currently owns a total of 1 stock. Hyam Levitsky owns 116,700 shares of Juno Therapeutics Inc (JUNO) as of June 17, 2016, with a value of $10 Million.
Latest Holdings of Hyam Levitsky
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| JUNO | Juno Therapeutics Inc | 2016-06-17 | 116,700 | 86.96 | 10,148,232 |
Holding Weightings of Hyam Levitsky
Hyam Levitsky Form 4 Trading Tracker
According to the SEC Form 4 filings, Hyam Levitsky has made a total of 0 transactions in Juno Therapeutics Inc (JUNO) over the past 5 years. The most-recent trade in Juno Therapeutics Inc is the sale of 12,418 shares on June 17, 2016, which brought Hyam Levitsky around $531,118.
Insider Trading History of Hyam Levitsky
- 1
Hyam Levitsky Trading Performance
Hyam Levitsky Ownership Network
Ownership Network List of Hyam Levitsky
Ownership Network Relation of Hyam Levitsky
Hyam Levitsky Owned Company Details
What does Replimune Group Inc do?
Who are the key executives at Replimune Group Inc?
Hyam Levitsky is the director of Replimune Group Inc. Other key executives at Replimune Group Inc include Chief Commercial Officer Sushil Patel , Chief Commercial Officer Christopher Sarchi , and Chief Medical Officer Konstantinos Xynos .
Replimune Group Inc (REPL) Insider Trades Summary
Over the past 18 months, Hyam Levitsky made no insider transaction in Replimune Group Inc (REPL). Other recent insider transactions involving Replimune Group Inc (REPL) include a net sale of 36,807 shares made by Konstantinos Xynos , a net sale of 12,680 shares made by Christopher Sarchi , and a net sale of 30,194 shares made by Sushil Patel .
In summary, during the past 3 months, insiders sold 0 shares of Replimune Group Inc (REPL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 157,924 shares of Replimune Group Inc (REPL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 157,924 shares.
Replimune Group Inc (REPL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Replimune Group Inc Insider Transactions
Hyam Levitsky Mailing Address
Above is the net worth, insider trading, and ownership report for Hyam Levitsky. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Hyam Levitsky's mailing address is: New York Ny 10010.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
